NICE recommends psoriasis drugs Humira, Enbrel and Stelara in final guidance

The U.K.'s NICE issued final guidance for three plaque psoriasis drugs in specific populations of children and young people experiencing severe disease who have not responded to standard systemic therapy. NICE said severe is defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more.

The agency recommended Humira adalimumab from AbbVie Inc. (NYSE:ABBV) in patients at least four years old; Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN) in patients at least six years old; and Stelara ustekinumab from Johnson & Johnson (NYSE:JNJ) in patients at least 12 years old. ...